Trends in pharmacological emergency treatment of patients suffering from schizophrenia over a 16-year observation period. 2018

Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
Department of Psychiatry, Psychotherapy and Psychosomatics, Division of Psychiatry I, Medical University Innsbruck, Innsbruck, Austria.

Patients suffering from schizophrenia are often treated in locked psychiatric units because of psychomotor agitation, hostility and aggressive behavior, or suicidality. Because of legal conditions, investigations on these acutely ill patients are difficult, and many studies do not represent 'real-life psychiatry'. This retrospective survey was conducted at the Department of Psychiatry, Psychotherapy and Psychosomatics of the Medical University, Innsbruck, Austria. Data were collected from the records of all adult inpatients suffering from a schizophrenia spectrum disorder according to the International Classification of Diseases, 10th ed. (ICD-10) (F2x) who had been admitted to a locked unit in 1997, 2002, 2007, and 2012. In addition to demographic data, diagnoses at the time of admission, length of stay at the locked unit, and psychopharmacological treatment (3 h before and following admission) were recorded. The mean length of stay at a locked unit decreased significantly from 11.8±4.43 days (mean±SD) in 1997 to 8.5±12.96 days (mean±SD) in 2012. The use of antipsychotics decreased nonsignificantly from 1997 to 2012. Despite an increasing use of second compared with first-generation antipsychotic drugs over the course of time, haloperidol was the most frequently used single compound in all investigated years except 2012. The majority of medications were administered orally. The use of benzodiazepines did not change substantially over the course of time. All in all, pharmacological emergency treatment of patients suffering from schizophrenia spectrum disorders in locked units was in line with current treatment guidelines, which recommend the use of second-generation antipsychotic drugs, monotherapy, oral application, and cautious dosing.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011595 Psychomotor Agitation A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions. Agitation, Psychomotor,Akathisia,Excitement, Psychomotor,Restlessness,Psychomotor Hyperactivity,Psychomotor Restlessness,Hyperactivity, Psychomotor,Psychomotor Excitement,Restlessness, Psychomotor
D004638 Emergency Treatment First aid or other immediate intervention for accidents or medical conditions requiring immediate care and treatment before definitive medical and surgical management can be procured. Emergency Therapy,Therapy, Emergency,Emergency Therapies,Emergency Treatments,Therapies, Emergency,Treatment, Emergency,Treatments, Emergency
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006760 Hospitalization The confinement of a patient in a hospital. Hospitalizations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001317 Austria A country located in Central Europe, north of Italy and Slovenia. The capital is Vienna.

Related Publications

Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
September 2005, Schizophrenia research,
Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
August 1989, New York state journal of medicine,
Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
September 2023, Swiss dental journal,
Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
January 2024, International clinical psychopharmacology,
Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
February 2023, AEM education and training,
Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
May 2011, L'Encephale,
Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
January 2017, The Journal of continuing education in the health professions,
Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
March 1984, Neurochirurgia,
Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
January 1992, Leukemia,
Monika Edlinger, and Anna-Sophia Welte, and Nursen Yalcin-Siedentopf, and Georg Kemmler, and Felix Neymeyer, and W Wolfgang Fleischhacker, and Alex Hofer
May 2017, The Journal of surgical research,
Copied contents to your clipboard!